Weight loss

Weight loss concept
#Obesity #Roche #Type 2 diabetes #Weight loss #Zealand Pharma

Roche and Zealand drug shows 9.2% mean body weight reduction

Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes.  The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More

#News #Trending News

Muscle mass
#Atrogi #Muscle atrophy #Obesity #Weight loss

GRK2 modulator reduces fat mass while building muscle

Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator.  ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while… Read More

#News

Glucagon-like peptide 1
#GLP-1 #Menarini #Mergers and acquisitions #Obesity #Weight loss

Gan & Lee and Menarini agree $843m deal for GLP-1 candidate

Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee's glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide.  The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks.  Under the agreement, Gan… Read More

#Business & Investment #News

#Alcohol Use Disorder #Clinical trials #GLP-1 #Semaglutide #Wegovy #Weight loss

Weight-loss pill may quieten alcohol cravings

New research has shown that people taking oral semaglutide – the active ingredient used in Wegovy – experienced fewer heavy-drinking days, consumed fewer drinks when they did drink and reported weaker everyday cravings than those given a placebo. The eight-week randomised clinical trial involved 50 adults with moderate-to-severe alcohol use… Read More

#News

Weight loss tablets
#Eli Lilly #GLP-1 #MHRA #Obesity #Type 2 diabetes #Weight loss

UK first in Europe to authorise Lilly’s weight loss tablet orforglipron

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and weight maintenance… Read More

#News #Regulatory

Clinical trial
#Obesity #Phase I trial #Verdiva Bio #Weight loss

Verdiva Bio initiates Phase I study of obesity drug

Verdiva Bio has dosed the first patient in a Phase I SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity.  The Phase I randomised, double-blind, placebo-controlled study will assess the safety and tolerability of VRB-103, in healthy patients with… Read More

#News

Retatrutide
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Phase III trials confirm benefits of Lilly’s triple agonist retatrutide

Eli Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist.   In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some… Read More

#News #Trending News

#China #GLP-1 #Market reporting #Metabolic diseases #Obesity #Weight loss

How advanced is China in diabetes drug discovery?

With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late 2025 revealed that China is emerging as a ‘global innovation… Read More

#Exclusive Content

Woman standing on scales
#Cardiometabolic diseases #GLP-1 #Weight loss

What the GLP-1 payer wars reveal about commercialisation strategy 

Janice MacLennan, Founder & CEO, Nmblr, explains why biopharma companies hoping to enter the competitive GLP-1 market need to build value narratives in parallel with scientific evidence.  The emergence of GLP-1 therapies is unprecedented, with the global GLP-1 receptor agonist market valued at $66.4 billion in 2025 and projected to reach $185.3 billion by 20331. This trajectory is set to… Read More

#Exclusive Content

Magic mushrooms
#Clinical trial #Drug discovery #Psilocybin #Weight loss

‘Magic mushroom’ compounds could help treat anorexia

Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says.  A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for… Read More

#News

#Clinical trial #GLP-1 #Obesity #Weight loss

What’s the outlook for GLP-1 therapeutics?

Is the honeymoon period over for GLP-1s or is the market yet to reach its full potential? Diana Turner asks what will differentiate the next generation of these peptide analogues.  Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which is also a GIP (glucose-dependent insulinotropic polypeptide) receptor, have… Read More

#Exclusive Content

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

#AdipoPharma #GLP-1 #Obesity #Weight loss

Could a new weight loss approach have longer term benefits than GLP-1s?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Vincent Marion, Scientific Founder and President of AdipoPharma. AdipoPharma is a biotech leveraging research on insulin resistance and adipose tissue biology, developing a new treatment for metabolic diseases. Vincent… Read More

#Featured Podcasts #Podcasts

#GLP-1 #MHRA #Obesity #UK #Weight loss

Wegovy pill could help patients lose 17% body weight 

The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show.  The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available… Read More

#News